Replies to post #116072 on Biotech Values

[oc631]

First SVR data for mericitabine (a.k.a RG7128 ) for the Jump-C phase 2b study.

Thanks for posting this abstract along with that from the NUCLEAR (938/7977) study. Roche may continue to push forward with the outdated PROPEL study in the hope (very unlikely IMO) that PSI-7977 stumbles on safety. Starting the GT2/3 trial would prove this program still has legs. I like the name (mericitabine) but I doubt it's a name anyone will remember in the next 10 years.

I'm still waiting to hear more on INFORM-SVR. In this case I feel no news is bad news for Roche.